Human Genetic Studies in Multiple Sclerosis
Large-scale genome-wide association studies have identified numerous risk loci for multiple sclerosis, mainly involving immune system pathways. This research portrays multiple sclerosis as a highly polygenic, immune-mediated disease.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Moderate
- Outcome
- Not reported
Why it matters
These findings enhance understanding of the genetic underpinnings of multiple sclerosis and may clarify why immune-modifying therapies are effective for this condition.
What this does not prove
The clinical relevance of these results is limited by low predictive power, small study sizes concerning disease severity, and challenges in applying findings across diverse populations.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-23
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceThe clinical relevance of multiple sclerosis genetics: from susceptibility to disease severity and progression. ↗DOI: 10.1016/s1474-4422(26)00356-x
Supporting passages (7)
study designPublication types: Journal Article; Review
subjectsThese findings help explain why immune-modifying therapies suppress relapses and new lesion formation.
limitationsthe direct clinical relevance of this research remains constrained by modest individual-level predictive value, underpowered studies of genetic determinants of disease severity and disability progression, complex regulatory mechanisms linking variants to function, and restricted generalisability across populations.
findingsLarge-scale genome-wide association studies have identified hundreds of multiple sclerosis risk loci, most of which implicate immune pathways and establish multiple sclerosis as a highly polygenic, immune-mediated disease. These findings help explain why immune-modifying therapies suppress relapses and new lesion formation.
publication datePublication date: 2026-10-23
peer reviewedJournal: The Lancet. Neurology
peer reviewedPublication types: Journal Article; Review
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.